Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most effective method to Pick the Right Teeth Substitution Choice for You - 2Key Little Things That Advantage Old People
- 3Are your hormones imbalanced? Doctors explain how to know if you need testing
- 4Most loved Occasion Dish: What Makes Your Merry Table?
- 5Two reportedly killed as Israel attacks Hezbollah targets in Lebanon
- SpaceX launches Italian Earth-observing satellite to orbit on the 1st mission of 2026 (video)
- Ocean side Locations for a Family Excursion
- Mississippi Insight for Jan. 11, 2026
- Step by step instructions to Protect Your Speculations with Cd Rates
- Investigate the Excellence of Professional flowerbeds: A Virtual Local escort
- Why Cannes Is the Ultimate New Year’s Eve Destination in the South of France’s Off-Season
- Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts.
- Mom finds out she has cancer after noticing something was off while breastfeeding
- US FDA grants market authorization to six on! PLUS nicotine pouch products
